ClinicalTrials.gg
Status unknownNCT03782480Updated Jan 31, 2019

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

A Phase 3 interventional study of Intrarosa and Placebos in Menopause, Genitourinary Syndrome of Menopause and Vulvovaginal Atrophy, sponsored by Center for Vulvovaginal Disorders. Status unknown at 2 sites in United States. Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-31.

Sponsored by Center for Vulvovaginal Disorders · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.

Planned enrollment
34th of 53
40 · median 60
Started
2019
with 2 others
Phase 3
13 of 56
none open now
Registered
39th of 56
by date

Among the 56 studies in Dyspareunia with a site in United States, this one is the 34th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2019, is one of 13 in phase 3, and was the 39th registered.

Dyspareunia

159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.

Browse Dyspareunia studies →

Open to participants now

8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 40 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Dyspareunia with a site in United States, or all of them as a file.
02

Study summary

Tissues of the genitals of women are both androgen (testosterone) and estrogen dependent. The clitoris, vestibule, urethra, anterior vaginal wall, peri-urethral tissue, and pelvic floor all depend on androgens for normal function. In addition, the glands, which secrete lubrication during sexual arousal, also require androgens to function. Deficiencies of both estrogens and androgens occur naturally during menopause. Menopause-related deficiencies of these hormones lead to thinning in the tissues of the genital and urinary systems which have been termed Genitourinary Syndrome of Menopause (GSM). Patients with GSM will frequently complain of dryness and/or pain during sexual intercourse.

Historically, GSM treatment involved both androgens and estrogens, However, over the past few decades estrogen based therapies have become much more common. More recently, clinical trials have demonstrated that local vaginal dehydroepiandrosterone (Intrarosa®) improves symptoms in menopausal women who have moderate to severe pain with intercourse.

Intrarosa® vaginal inserts are a prescription medicine approved by the U.S. Food and Drug Administration (FDA) used in women after menopause to treat moderate to severe pain during sexual intercourse caused by changes in and around the vagina that happen with menopause.

Read the detailed description

Tissues in the genitourinary system are both androgen- and estrogen-dependent. The clitoris, vestibule, urethra, anterior vaginal wall, peri-urethral tissue, and pelvic floor are androgen-responsive. In addition, the minor vestibular glands and the major vestibular glands (Bartholin's and Skene's) are androgen-dependent, mucin-secreting glands. Deficiencies of both estrogens and androgens can occur both naturally during menopause or iatrogenically because of certain medications (e.g. Depo Lupron, spironolactone) or surgically (oophorectomy). Menopause-related deficiencies of these sex hormones lead to atrophic changes in the genitourinary system which have been termed genitourinary syndrome of menopause (GSM).

While erythema is a nonspecific finding in atrophic tissue, focal painful erythema in the androgen-dependent vestibule, particularly near the ostia of the Bartholin's glands (4:00 and 8:00 o'clock) and Skene's glands (1:00 and 11:00 o'clock) or lesser vestibular glands, is highly suggestive of GSM. Patients with GSM will frequently complain of penetrative dyspareunia and experience allodynia with the cotton swab palpation of the vulvar vestibule. During examination of the vulvar vestibule, the examiner might note general pallor with superimposed erythema. Physical exam can be improved by magnification (i.e. vulvoscopy).

Historically, GSM treatment involved both androgens and estrogens. However, in the absence of information about intracrinology, over the past few decades, estradiol-based therapies have been used exclusively. More recently, double-blind, placebo controlled clinical trials demonstrated that local vaginal dehydroepiandrosterone (Intrarosa®) improves symptoms in postmenopausal women including moderate to severe dyspareunia. These trials have demonstrated improvement in both subjective measures (such as improvement in dyspareunia) as well as objective measurement of vaginal health (improved vaginal maturation index, decreased vaginal pH) but they have not attempted to demonstrate improvement in the health of the vulvar tissue.

03

Conditions studied

  • Menopause
  • Genitourinary Syndrome of Menopause
  • Vulvovaginal Atrophy
  • Menopause Syndrome
  • Dyspareunia

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women aged 40 to 80 years.
  2. Women who have self-identified at screening pain at sexual activity as moderate to severe and most bothersome symptom of vulvovaginal atrophy (Refer to Vaginal Atrophy Symptoms Questionnaire (VASQ-MBS)).
  3. Women having ≤5% of superficial cells on vaginal smear at screening.
  4. Women having a vaginal pH above 5 at screening.
  5. Willing to participate in the study and sign an .

Exclusion criteria

Exclusion Criteria:

  1. metabolic or endocrine disease (including diabetes mellitus) not controlled by medication.
  2. Use of estrogen injectable drug therapy and/or progestin implant within 6 months prior to screening visit.
  3. Oral estrogen, progestin or DHEA exposure or intrauterine progestin therapy within 8 weeks prior to screening visit.
  4. Vaginal hormonal products (rings, creams, gels or tablets) or transdermal estrogen alone or estrogen/progestin products within 8 weeks prior to screening visit.
  5. Previous treatment with androgens or anabolic steroids within 3 months prior to screening visit (see Appendix 15.1 - Concomitant medications).
  6. Confirmed clinically significant depression (not controlled by standard therapy) or confirmed history of severe psychiatric disturbance.
  7. The administration of any drug within 30 days of screening visit.
  8. Clinically significant abnormal serum biochemistry, urinalysis or hematology (as per Investigator's assessment who should take into account the patient's pre-baseline conditions).
  9. Uterine palpable fibroids.
  10. Uterine prolapse (when the cervix reaches labia minora at gynecologic exam).
  11. Subjects who suffer from vulvar lichen sclerosus or any vulvar dermatological disorder that affects the vulvar vestibule or vagina.
  12. Chronic use of narcotics or alcoholism during the last 5 years.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Intrarosa

    Daily intravaginal administration at bedtime of one insert containing 6.5mg (0.50%) prasterone for 26 weeks

    Drug: Intrarosa

  • Placebo comparator
    Placebo

    Daily intravaginal administration at bedtime of one insert containing placebo for 26 weeks

    Drug: Placebos

Interventions

06

What researchers measure

Primary outcomes

  1. Changes from baseline in morphological content of vulvar and vaginal cells

    Changes from baseline in density of androgen, estrogen and progesterone receptors. Unit of measure to be determined.

    Time frame: 2 years

  2. Changes from baseline in morphological content of vulvar and vaginal cells

    Changes from baseline in tissue steroid concentrations. Unit of measure to be determined.

    Time frame: 2 years

  3. Changes from baseline in morphological content of vulvar and vaginal cells

    Changes from baseline in blood steroid concentration. Unit of measure to be determined.

    Time frame: 2 years

  4. Changes from baseline in protein content of vulvar and vaginal cells

    Changes from baseline in mucin. Unit of measure to be determined.

    Time frame: 2 years

  5. Changes from baseline in enzymatic content of vulvar and vaginal cells

    Changes from baseline in enzymatic content (HSD17B5, HSD3B1, 5alphaRED2, aromatase, HDS17B1, sulfotransferase 2A1, sulfatase and UGT2B). All enzymes have the same unit of measure. Unit of measure to be determined.

    Time frame: 2 years

  6. Changes from baseline in antigen content of vulvar and vaginal cells

    Changes from baseline in PGP9.5. Unit of measure to be determined.

    Time frame: 2 years

  7. Changes from baseline in antigen content of vulvar and vaginal cells

    Changes from baseline in Ki-67 antigen. Unit of measure to be determined.

    Time frame: 2 years

Secondary outcomes

  1. Mean change from baseline in subject's scores on pain severity subscale VPAQ

    The Vulvar Pain Assessment Questionnaire (VPAQ) was developed to assess the dimensions of the pain experience in studies of chronic pain. It consists of 6 primary (pain severity, emotional response, cognitive response, and interference with life, sexual function, and self-stimulation/penetration) and 3 supplementary subscales (pain quality, coping skills, and partner factors). The pain severity subscale of the VPAQ consists of 3 pairs of verbal rating scale that test both pain intensity and pain affect. Each verbal rating scale is a 5-point scale with the following options: none=0, mild=1, moderate=2, severe=3, and worst possible=4. The calculated mean produces the overall score for the pain severity subscale ranging from 0-4 (4 is the worst score).

    Time frame: 2 years

07

Study locations

2 of 2 sites recruiting
  • The Centers for Vulvovaginal Disorders
    Washington, District of Columbia 20037, United States
    Recruiting
    • Leia Mitchell, MSc · Contactleiam.cvvd@gmail.com · 202-887-0568
    • Andrew T Goldstein, MD · Principal investigator
    • Sarah Cigna, MD · Sub investigator
  • The Centers for Vulvovaginal Disorders
    New York, New York 10036, United States
    Recruiting
    • Leia Mitchell, MSc · Contactleiam.cvvd@gmail.com · 202-887-0568
    • Andrew T Goldstein, MD · Principal investigator
08

References and documents

Publications

  • Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017 Apr;24(4):452-461. doi: 10.1097/GME.0000000000000768. PubMed 27875388 ↗
  • Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Int J Womens Health. 2010 Aug 9;1:105-11. doi: 10.2147/ijwh.s4872. PubMed 21072280 ↗
  • Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014 Feb;17(1):3-9. doi: 10.3109/13697137.2013.871696. PubMed 24423885 ↗
  • Labrie F. Intracrinology. Mol Cell Endocrinol. 1991 Jul;78(3):C113-8. doi: 10.1016/0303-7207(91)90116-a. PubMed 1838082 ↗
  • Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Cote I, Lavoie L, Martel C, Balser J; VVA Prasterone Group. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015 Sep;22(9):950-63. doi: 10.1097/GME.0000000000000428. PubMed 25734980 ↗
  • Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Cote I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur E; VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016 Mar;23(3):243-56. doi: 10.1097/GME.0000000000000571. PubMed 26731686 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2019; primary completion for Jan 2021, 22 months later.

Of 10 phase 3 interventional studies under Dyspareunia, half reached primary completion within 13 months of starting (the median); a quarter within 5 and three quarters within 28. This study's planned 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2018
First posted
Dec 20, 2018
StartEst.
Mar 2, 2019
Primary completionEst.
Jan 2, 2021
CompletionEst.
Jan 2, 2021
Last update
Jan 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03782480
Lead sponsor
Center for Vulvovaginal Disorders
Collaborators
EndoCeutics Inc.
Responsible party
Andrew T. Goldstein, MD (Study Principle Investigator, Center for Vulvovaginal Disorders) — Principal investigator
First posted
Dec 20, 2018
Start date
Mar 2, 2019 (estimated)
Primary completion
Jan 2, 2021 (estimated)
Completion
Jan 2, 2021 (estimated)
Last update
Jan 31, 2019

Study contacts

Leia Mitchell, MSc
Contact
leiam.cvvd@gmail.com
2028870568
Leia Mitchell
Contact
leiam.cvvd@gmail.com
2028870568
Fernand Labrie, MD
study director · EndoCeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dehydroepiandrosterone

Start the discussion